Literature DB >> 22464367

Immunologic and genetic markers in patients with idiopathic ocular inflammation and a family history of inflammatory bowel disease.

Javaneh Abbasian1, Tammy M Martin, Sarju Patel, Howard H Tessler, Debra A Goldstein.   

Abstract

PURPOSE: To evaluate the prevalence of immunologic and genetic markers in patients with idiopathic ocular inflammation and a family history of inflammatory bowel disease.
DESIGN: Matched case-control study.
METHODS: Patients with a diagnosis of idiopathic ocular inflammation and family history of inflammatory bowel disease who did not have inflammatory bowel disease themselves were identified and matched to control patients with idiopathic ocular inflammation. Serum was evaluated for immunologic markers using Prometheus IBD Serology 7. Genomic DNA was analyzed for single nucleotide polymorphisms (SNP) of the NOD2 gene associated with Crohn disease.
RESULTS: Fifteen patients with idiopathic ocular inflammation and family history of inflammatory bowel disease were matched to 15 control patients based on age, sex, and race. Eight of 15 patients (53%) with a family history of inflammatory bowel disease had elevated p-ANCA antibody levels compared to 3 of 15 controls (20%) (1-sided P = .04) with a matched analysis odds ratio of 6.0 (1-sided P = .06). Four of 15 patients (27%) with family history of inflammatory bowel disease tested positive for immunologic markers predicting ulcerative colitis, while no control patients tested positive (1-sided P = .06). Carrier rates of NOD2 SNPs did not differ significantly between the test and control groups.
CONCLUSIONS: One-quarter of patients with idiopathic ocular inflammation and a family history of inflammatory bowel disease had immunologic markers predicting bowel disease, and one-half had elevated p-ANCA levels. Prometheus IBD Serology 7 may be useful in the evaluation of selected patients with unexplained uveitis.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22464367      PMCID: PMC3973432          DOI: 10.1016/j.ajo.2012.01.016

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  31 in total

1.  Marker antibody expression stratifies Crohn's disease into immunologically homogeneous subgroups with distinct clinical characteristics.

Authors:  E A Vasiliauskas; L Y Kam; L C Karp; J Gaiennie; H Yang; S R Targan
Journal:  Gut       Date:  2000-10       Impact factor: 23.059

Review 2.  Current view of the immunopathogenesis in inflammatory bowel disease and its implications for therapy.

Authors:  M-I Torres; A Rios
Journal:  World J Gastroenterol       Date:  2008-04-07       Impact factor: 5.742

Review 3.  Ileocolonoscopic findings in seronegative spondylarthropathies.

Authors:  H Mielants; E M Veys; C Cuvelier; M de Vos
Journal:  Br J Rheumatol       Date:  1988

4.  The extra-intestinal complications of Crohn's disease and ulcerative colitis: a study of 700 patients.

Authors:  A J Greenstein; H D Janowitz; D B Sachar
Journal:  Medicine (Baltimore)       Date:  1976-09       Impact factor: 1.889

5.  Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease.

Authors:  J P Hugot; M Chamaillard; H Zouali; S Lesage; J P Cézard; J Belaiche; S Almer; C Tysk; C A O'Morain; M Gassull; V Binder; Y Finkel; A Cortot; R Modigliani; P Laurent-Puig; C Gower-Rousseau; J Macry; J F Colombel; M Sahbatou; G Thomas
Journal:  Nature       Date:  2001-05-31       Impact factor: 49.962

6.  A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease.

Authors:  Y Ogura; D K Bonen; N Inohara; D L Nicolae; F F Chen; R Ramos; H Britton; T Moran; R Karaliuskas; R H Duerr; J P Achkar; S R Brant; T M Bayless; B S Kirschner; S B Hanauer; G Nuñez; J H Cho
Journal:  Nature       Date:  2001-05-31       Impact factor: 49.962

7.  CARD15/NOD2 mutational analysis and genotype-phenotype correlation in 612 patients with inflammatory bowel disease.

Authors:  Suzanne Lesage; Habib Zouali; Jean-Pierre Cézard; Jean-Frédéric Colombel; Jacques Belaiche; Sven Almer; Curt Tysk; Colm O'Morain; Miquel Gassull; Vibeke Binder; Yigael Finkel; Robert Modigliani; Corinne Gower-Rousseau; Jeanne Macry; Françoise Merlin; Mathias Chamaillard; Anne-Sophie Jannot; Gilles Thomas; Jean-Pierre Hugot
Journal:  Am J Hum Genet       Date:  2002-03-01       Impact factor: 11.025

Review 8.  Genetics of inflammatory bowel disease: progress and prospects.

Authors:  Christopher G Mathew; Cathryn M Lewis
Journal:  Hum Mol Genet       Date:  2004-02-05       Impact factor: 6.150

9.  Familial aggregation in seronegative spondyloarthritis of enterogenic origin. A family study.

Authors:  H Mielants; E M Veys; R Joos; S Suykens; C Cuvelier; M De Vos
Journal:  J Rheumatol       Date:  1986-02       Impact factor: 4.666

Review 10.  Ocular manifestations of inflammatory bowel disease.

Authors:  Roni Mintz; Edward R Feller; Robert L Bahr; Samir A Shah
Journal:  Inflamm Bowel Dis       Date:  2004-03       Impact factor: 5.325

View more
  4 in total

1.  Ocular Manifestations in Inflammatory Bowel Disease Are Associated with Other Extra-intestinal Manifestations, Gender, and Genes Implicated in Other Immune-related Traits.

Authors:  Sasha Taleban; Dalin Li; Stephan R Targan; Andrew Ippoliti; Steven R Brant; Judy H Cho; Richard H Duerr; John D Rioux; Mark S Silverberg; Eric A Vasiliauskas; Jerome I Rotter; Talin Haritunians; David Q Shih; Marla Dubinsky; Gil Y Melmed; Dermot P B McGovern
Journal:  J Crohns Colitis       Date:  2015-10-08       Impact factor: 9.071

2.  Prevalence and characteristics of ophthalmological extra-intestinal manifestations in Chinese patients with inflammatory bowel disease.

Authors:  Ying-Chao Li; Wei-Zhi Li; Chang-Rui Wu; Yun Feng; Li Ren; Chen Mi; Yang Li
Journal:  Int J Ophthalmol       Date:  2016-10-18       Impact factor: 1.779

Review 3.  Ophthalmic manifestations in patients with inflammatory bowel disease: A review.

Authors:  Leandro Lopes Troncoso; Ana Luiza Biancardi; Haroldo Vieira de Moraes; Cyrla Zaltman
Journal:  World J Gastroenterol       Date:  2017-08-28       Impact factor: 5.742

Review 4.  Biomarkers of inflammatory bowel disease.

Authors:  Yi Fengming; Wu Jianbing
Journal:  Dis Markers       Date:  2014-05-19       Impact factor: 3.434

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.